Vanguard Group Inc. lowered its holdings in shares of Indivior PLC (NASDAQ:INDV - Free Report) by 3.1% in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 4,559,682 shares of the company's stock after selling 144,104 shares during the period. Vanguard Group Inc. owned about 3.31% of Indivior worth $58,405,000 as of its most recent filing with the SEC.
Other institutional investors and hedge funds have also modified their holdings of the company. Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Indivior in the fourth quarter worth about $56,000. Stifel Financial Corp bought a new position in Indivior in the 3rd quarter valued at approximately $100,000. Jane Street Group LLC bought a new position in Indivior in the 3rd quarter valued at approximately $180,000. Public Employees Retirement System of Ohio acquired a new stake in Indivior in the third quarter valued at approximately $294,000. Finally, China Universal Asset Management Co. Ltd. bought a new stake in shares of Indivior during the fourth quarter worth $359,000. 60.33% of the stock is currently owned by institutional investors.
Indivior Stock Performance
Shares of INDV traded down $0.07 during mid-day trading on Wednesday, reaching $9.04. 487,138 shares of the company were exchanged, compared to its average volume of 931,390. The business has a 50 day simple moving average of $9.54 and a two-hundred day simple moving average of $10.34. The stock has a market capitalization of $1.25 billion, a PE ratio of -25.83 and a beta of 0.93. Indivior PLC has a 52 week low of $7.33 and a 52 week high of $19.78.
Indivior (NASDAQ:INDV - Get Free Report) last posted its quarterly earnings data on Thursday, February 20th. The company reported $0.32 EPS for the quarter, meeting analysts' consensus estimates of $0.32. Indivior had a negative net margin of 3.96% and a negative return on equity of 241.73%. The company had revenue of $298.00 million for the quarter, compared to analyst estimates of $262.35 million. On average, analysts predict that Indivior PLC will post 1.22 EPS for the current year.
Wall Street Analysts Forecast Growth
A number of equities research analysts recently weighed in on INDV shares. Rodman & Renshaw assumed coverage on Indivior in a research report on Tuesday, January 28th. They set a "buy" rating and a $16.00 price objective on the stock. Piper Sandler lowered their price objective on Indivior from $16.00 to $13.00 and set an "overweight" rating for the company in a research note on Thursday, March 6th. Finally, RODMAN&RENSHAW upgraded shares of Indivior to a "strong-buy" rating in a report on Tuesday, January 28th.
Check Out Our Latest Stock Analysis on INDV
Indivior Profile
(
Free Report)
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.
Read More
Before you consider Indivior, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Indivior wasn't on the list.
While Indivior currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn how options trading can help you navigate market volatility, manage risk, and maximize returns with MarketBeat's "Unlock the Potential in Options Trading." Click the link below to have this special report delivered to your inbox.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
